학술논문
Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)
Document Type
Article
Author
Source
In: Annals of Surgical Oncology . (Annals of Surgical Oncology, July 2024, 31(7):4621-4633)
Subject
Language
English
ISSN
15344681
10689265
10689265